In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Trevena, Inc.. Trade Record

NASDAQ:TRVN Trevena, Inc. stock gains 28.27% Exit Feb 20, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart TRVN Feb 4, 2019, priceSeries
About Trevena, Inc.

Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include oliceridine injection, a µ-receptor G protein pathway selective modulator, which is in Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in preclinical development for the treatment of migraine; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. Trevena, Inc. was founded in 2007 and is headquartered in King of Prussia, Pennsylvania.

Trade Information
Trade Type
LONG
ReliabilityScore™
98.31
Entry Date
Feb 4, 2019
Entry Price
1.12
Sell Date
Feb 20, 2019
Sell Price
1.44
Net Gain
28.27%
Hold Time
11 Trading Days